On 25 February 2026, India-headquartered Shilpa Biologics and Costa Rican-based SteinCares announced they have entered into a licensing agreement for commercialisation of an undisclosed biosimilar in Latin America.
Under the agreement, SteinCares will have exclusive rights to register, commercialise and distribute the biosimilar across Latin America, while Shilpa will be responsible for product development, manufacture and supply to SteinCares. The collaboration provides Shilpa’s first entry into the Latin American market.
SteinCares has existing partnerships with companies seeking to commercialise their biosimilars across Latin America. In June 2025, SteinCares and Bio-Thera entered into an agreement to commercialise biosimilar dupilumab across Latin America, which was the fourth product the companies have collaborated on in the region.